1. ALLA AKTIER
  2. NYHETER
  3. NEWBURY PHARMACEUTICALS

Newbury Pharmaceuticals

Nyheter Newbury Pharmaceuticals Nyheter alla bolag
Hej Visste du att du med vår premiumtjänst får fullständig historik i alla grafer, pressmeddelanden och andra notiser för dina favoritbolag direkt som DM i Discord samt en del andra godsaker? Du slipper dessutom störande annonser på sajten. Testa gratis i 14 dagar!

Newbury Pharmaceuticals Secures Generic Approval for Buspiron

Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Buspiron tablets in Sweden.

“Buspirone is a medication for anxiety (anxiolytic) that works by affecting certain natural substances in the brain (neurotransmitters). Based on this positive outcome of the regulatory process, we will proceed to launch this product” says Mr Lars Minor CEO of Newbury

 The annual value of the market is estimated to be 0,9 MEUR according to DLMI Nordic Pharma Insights.

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

Newbury Pharmaceuticals Secures Generic Approval for Buspiron

Datum 2024-10-28, kl 10:00
Källa MFN
Bifogade filer
Newbury Pharmaceuticals Secures Generic Approval for Buspiron